[{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BMF-219","moa":"||Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"}]
Find Clinical Drug Pipeline Developments & Deals by Biomea Fusion
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
